PCVX logo

Vaxcyte, Inc. (PCVX) EBITDA

annual EBITDA:

-$448.08M-$55.99M(-14.28%)
December 31, 2024

Summary

  • As of today (September 14, 2025), PCVX annual EBITDA is -$448.08 million, with the most recent change of -$55.99 million (-14.28%) on December 31, 2024.
  • During the last 3 years, PCVX annual EBITDA has fallen by -$351.47 million (-363.79%).
  • PCVX annual EBITDA is now -1479.25% below its all-time high of -$28.37 million, reached on December 31, 2018.

Performance

PCVX EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCVXincome statement metrics

quarterly EBITDA:

-$221.23M-$45.31M(-25.76%)
June 30, 2025

Summary

  • As of today (September 14, 2025), PCVX quarterly EBITDA is -$221.23 million, with the most recent change of -$45.31 million (-25.76%) on June 30, 2025.
  • Over the past year, PCVX quarterly EBITDA has dropped by -$71.73 million (-47.98%).
  • PCVX quarterly EBITDA is now -2037.07% below its all-time high of -$10.35 million, reached on June 30, 2019.

Performance

PCVX quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCVXincome statement metrics

TTM EBITDA:

-$584.87M-$71.73M(-13.98%)
June 30, 2025

Summary

  • As of today (September 14, 2025), PCVX TTM EBITDA is -$584.87 million, with the most recent change of -$71.73 million (-13.98%) on June 30, 2025.
  • Over the past year, PCVX TTM EBITDA has dropped by -$82.36 million (-16.39%).
  • PCVX TTM EBITDA is now -4276.44% below its all-time high of -$13.36 million, reached on March 31, 2019.

Performance

PCVX TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCVXincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

PCVX EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-14.3%-48.0%-16.4%
3 y3 years-363.8%-377.2%-329.5%
5 y5 years-814.4%-1008.1%-712.3%

PCVX EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-363.8%at low-377.2%at low-329.5%at low
5 y5-year-814.4%at low-1008.1%at low-712.3%at low
alltimeall time-1479.3%at low-2037.1%at low-4276.4%at low

PCVX EBITDA History

DateAnnualQuarterlyTTM
Jun 2025
-
-$221.23M(+25.8%)
-$584.87M(+14.0%)
Mar 2025
-
-$175.92M(+234.6%)
-$513.14M(+14.4%)
Dec 2024
-$448.08M(+14.3%)
-$52.58M(-61.1%)
-$448.60M(-15.2%)
Sep 2024
-
-$135.14M(-9.6%)
-$528.74M(+5.2%)
Jun 2024
-
-$149.50M(+34.2%)
-$502.50M(+15.4%)
Mar 2024
-
-$111.38M(-16.1%)
-$435.28M(+11.0%)
Dec 2023
-$392.10M(+83.2%)
-$132.71M(+21.9%)
-$392.10M(+17.1%)
Sep 2023
-
-$108.91M(+32.4%)
-$334.88M(+18.9%)
Jun 2023
-
-$82.28M(+20.7%)
-$281.53M(+14.6%)
Mar 2023
-
-$68.20M(-9.7%)
-$245.61M(+14.7%)
Dec 2022
-$214.03M
-$75.49M(+35.9%)
-$214.10M(+29.0%)
Sep 2022
-
-$55.56M(+19.9%)
-$165.97M(+21.9%)
Jun 2022
-
-$46.36M(+26.3%)
-$136.16M(+20.9%)
DateAnnualQuarterlyTTM
Mar 2022
-
-$36.69M(+34.1%)
-$112.61M(+14.3%)
Dec 2021
-$96.61M(+10.0%)
-$27.36M(+6.2%)
-$98.54M(+7.6%)
Sep 2021
-
-$25.76M(+13.0%)
-$91.58M(+5.9%)
Jun 2021
-
-$22.80M(+0.8%)
-$86.51M(+3.4%)
Mar 2021
-
-$22.62M(+10.8%)
-$83.67M(-4.7%)
Dec 2020
-$87.81M(+79.2%)
-$20.41M(-1.3%)
-$87.81M(+7.5%)
Sep 2020
-
-$20.68M(+3.6%)
-$81.68M(+13.4%)
Jun 2020
-
-$19.96M(-25.4%)
-$72.00M(+15.4%)
Mar 2020
-
-$26.75M(+87.3%)
-$62.39M(+27.3%)
Dec 2019
-$49.00M(+72.7%)
-$14.28M(+29.8%)
-$49.00M(+41.1%)
Sep 2019
-
-$11.00M(+6.3%)
-$34.72M(+46.4%)
Jun 2019
-
-$10.35M(-22.5%)
-$23.72M(+77.5%)
Mar 2019
-
-$13.36M
-$13.36M
Dec 2018
-$28.37M
-
-

FAQ

  • What is Vaxcyte, Inc. annual EBITDA?
  • What is the all time high annual EBITDA for Vaxcyte, Inc.?
  • What is Vaxcyte, Inc. annual EBITDA year-on-year change?
  • What is Vaxcyte, Inc. quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Vaxcyte, Inc.?
  • What is Vaxcyte, Inc. quarterly EBITDA year-on-year change?
  • What is Vaxcyte, Inc. TTM EBITDA?
  • What is the all time high TTM EBITDA for Vaxcyte, Inc.?
  • What is Vaxcyte, Inc. TTM EBITDA year-on-year change?

What is Vaxcyte, Inc. annual EBITDA?

The current annual EBITDA of PCVX is -$448.08M

What is the all time high annual EBITDA for Vaxcyte, Inc.?

Vaxcyte, Inc. all-time high annual EBITDA is -$28.37M

What is Vaxcyte, Inc. annual EBITDA year-on-year change?

Over the past year, PCVX annual EBITDA has changed by -$55.99M (-14.28%)

What is Vaxcyte, Inc. quarterly EBITDA?

The current quarterly EBITDA of PCVX is -$221.23M

What is the all time high quarterly EBITDA for Vaxcyte, Inc.?

Vaxcyte, Inc. all-time high quarterly EBITDA is -$10.35M

What is Vaxcyte, Inc. quarterly EBITDA year-on-year change?

Over the past year, PCVX quarterly EBITDA has changed by -$71.73M (-47.98%)

What is Vaxcyte, Inc. TTM EBITDA?

The current TTM EBITDA of PCVX is -$584.87M

What is the all time high TTM EBITDA for Vaxcyte, Inc.?

Vaxcyte, Inc. all-time high TTM EBITDA is -$13.36M

What is Vaxcyte, Inc. TTM EBITDA year-on-year change?

Over the past year, PCVX TTM EBITDA has changed by -$82.36M (-16.39%)
On this page